Revenue of $647.1 million , an increase of $178.0 million or 37.
9% , from the three months ended June 30, 2023 . Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.
4) million and a net loss margin of (1.0)% . Adjusted EBITDA of $52.
0 million resulting in an Adjusted EBITDA margin of 8.0% . Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.
Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024. WASHINGTON , Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc.
(NYSE: EVH ), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended June 30, 2024 . Seth Blackley , co-founder and Chief Executive Officer of Evolent stated, "Evolent revenue increased by over 35% year-over-year and we delivered consistent profitability and cash flow. We have also made significant progress toward revenue fee increases consistent with the higher disease rates in the market – underscoring our ability to perform and bring clinical value to our customers in both higher and lower utilization environments.
Mr. Blackley continued, "We believe the combination of our strong sales performance, the significant progress on updated rates and the clinical value we bring to our customers gives us confidence in delivering on our 2024 revised Adjusted EBITDA.